key: cord-1038389-0en9x1v2 authors: Ballman, Madison; Swift, Shannon; Mullenix, Cristina; Mallory, Yvonne; Zhao, Chen; Szabo, Eva; Shelat, Meenakshi; Sansone, Susan; Steinberg, Seth M.; McAdams, Meredith J.; Rajan, Arun title: Brief Report: Tolerability of COVID-19 Vaccines, BNT162b2 and mRNA-1273, in Patients with Thymic Epithelial Tumors date: 2021-09-08 journal: JTO Clin Res Rep DOI: 10.1016/j.jtocrr.2021.100229 sha: 950fc43ecf703a511cd2c278b7656cdf8a84b7d0 doc_id: 1038389 cord_uid: 0en9x1v2 Introduction Defects in immunological self-tolerance result in an increased risk for development of autoimmune paraneoplastic diseases (AD) and immune-mediated toxicity in response to immune stimulation in individuals with thymic epithelial tumors (TETs). We conducted a survey to evaluate the tolerability of Covid-19 messenger RNA (mRNA) vaccines in patients with TETs, including individuals with pre-existing AD. Methods After reviewing published data on adverse events (AEs) associated with the BNT162b2 (Pfizer, Inc., and BioNTech) and mRNA-1273 (ModernaTX, Inc.) mRNA vaccines, we designed and administered a questionnaire to participants at three timepoints: after each dose of vaccination and one month following the final dose. Questions related to AD and use of immunosuppressive drugs were included. Descriptive statistics were used to analyze data and results were compared with previously described results related to the BNT162b2 and mRNA-1273 vaccines. Results From February 26th and June 1st, 2021, we administered the survey to 54 participants (median age: 58 years; thymoma: 33; pre-existing AD: 19). Common AEs included injection-site pain, fatigue, and headaches. There were no vaccination-related hospitalizations or deaths. Autoimmune flares occurred in three (16%) patients after the first dose and three (17%) patients after the second dose. The majority of AD flares were mild and self-limited. One patient (2%) was diagnosed with a new AD following vaccination. Conclusions Tolerability of COVID-19 mRNA vaccines in patients with TETs is comparable to the general population. Most patients with pre-existing AD did not experience disease flares and the development of new AD was rare. Patients with TETs should be encouraged to get vaccinated against COVID-19 due to the documented benefits of vaccination and manageable risk profile. Defects in immunological self-tolerance result in an increased risk for development of autoimmune paraneoplastic diseases (AD) and immune-mediated toxicity in response to immune stimulation in individuals with thymic epithelial tumors (TETs). We conducted a survey to evaluate the tolerability of Covid-19 messenger RNA (mRNA) vaccines in patients with TETs, including individuals with pre-existing AD. After reviewing published data on adverse events (AEs) associated with the BNT162b2 (Pfizer, Inc., and BioNTech) and mRNA-1273 (ModernaTX, Inc.) mRNA vaccines, we designed and administered a questionnaire to participants at three timepoints: after each dose of vaccination and one month following the final dose. Questions related to AD and use of immunosuppressive drugs were included. Descriptive statistics were used to analyze data and results were compared with previously described results related to the BNT162b2 and mRNA-1273 vaccines. From February 26 th and June 1 st , 2021, we administered the survey to 54 participants (median age: 58 years; thymoma: 33; pre-existing AD: 19) . Common AEs included injection-site pain, fatigue, and headaches. There were no vaccination-related hospitalizations or deaths. Autoimmune flares occurred in three (16%) patients after the first dose and three (17%) patients after the second dose. The majority of AD flares were mild and self-limited. One patient (2%) was diagnosed with a new AD following vaccination. J o u r n a l P r e -p r o o f Introduction Thymomas and thymic carcinomas, collectively referred to as thymic epithelial tumors (TETs) are rare thoracic cancers with an incidence of 1.5 cases per million. 1, 2 TETs, particularly thymomas, are often associated with paraneoplastic autoimmune diseases (AD) due to impaired immunological self-tolerance resulting from the persistence of autoreactive T cells. 1, [3] [4] [5] [6] Due to these underlying defects in immunological tolerance, patients with TETs display increased sensitivity to immune stimulation. 2 Treatment with immune checkpoint inhibitors or cancer vaccines intended to stimulate the immune system can cause severe immune-related adverse events (irAEs) in 3% to 57% of patients. 2, 7, 8 This reactivity raises questions about the tolerability of other forms of immune stimulation, such as vaccination against COVID-19 in patients with TETs. At the time of study design, two messenger RNA (mRNA) vaccines had received emergency use authorization from the United States Food and Drug Administration for vaccination against COVID-19: BNT162b2 manufactured by Pfizer, Inc. and BioNTech, and mRNA-1273 produced by ModernaTX, Inc.. Phase II/III trial data demonstrates that both vaccines are safe and highly effective at preventing severe COVID-19 infection, hospitalization, and death. 9,10 Despite inclusion of a small number of participants with a history of AD in clinical trials evaluating the BNT162b2 vaccine, no specific safety concerns were observed after subgroup analysis by medical comorbidities. 9 Development of AD was not observed after vaccination with mRNA-1273 either, except for one case of rheumatoid arthritis following the second dose of the vaccine, which was considered not related to vaccination. 10 Taken together, these data do not indicate an J o u r n a l P r e -p r o o f increased risk of developing new AD or a flare of a previously existing AD following vaccination with the BNT162b2 or mRNA-1273 vaccines. In view of the unique immune biology of TETs and absence of data regarding tolerability of COVID-19 vaccines in this population, we conducted the following study to determine the tolerability of vaccination in adults with TETs. Individuals 18 years or older with active or previously treated thymoma or thymic carcinoma, with or without paraneoplastic AD who had received vaccination against COVID-19 were invited to participate in this survey. Participants had either received care at the NIH Clinical Center or were in the process of screening for ongoing NIH institutional review board (IRB)approved clinical trials. Consenting patients were interviewed in person during scheduled clinic visits or by means of a phone call. The study questionnaire was designed based on solicited local and systemic adverse events (AEs) reported within seven days of BNT162b2 and mRNA-1273 vaccination in participants aged 18 and older (details in Supplemental Appendix). All efforts were made to conduct interviews within one week following each dose of the vaccine and within one month following the second dose to correspond to the BNT162b2 and mRNA-1273 data collection timepoints. Information was collected about TET histology, patient age, presence or absence of thymomarelated AD, and the use of concomitant medications including immunosuppressive drugs. Data was de-identified and secured per institutional guidelines. The study was reviewed by the NIH IRB and determined to meet criteria for category 2 of exempt human subjects' research. Statistical analysis was conducted using descriptive statistics. A two-sided Fisher's exact test was used for appropriate paired comparison to evaluate differences in tolerability of BNT162b2 and mRNA-1273 vaccines in patients with TETs and individuals without TETs as reported from published vaccine clinical trial results. The frequency and relative risk of developing AEs was calculated for each group. Since this is an initial effort to evaluate the tolerability of COVID-19 mRNA vaccines in patients with TETs, power calculations were not performed for a study of this nature. However, with a minimum of 50 participants, the study was expected to provide indications about differences in tolerability of vaccination among individuals with and without TETs. Table 2 and Table 1 Two patients were diagnosed with new AD after receiving the first dose of the mRNA-1273 vaccine: one patient with autoimmune alopecia who had been symptomatic for several months but had sought medical attention after vaccination, and another patient with chronic idiopathic urticaria presenting as a full-body rash that responded temporarily to oral corticosteroids but recurred after discontinuation of steroids and has not resolved at the time of data cutoff. To our knowledge this survey represents the first attempt to systematically assess the tolerability of COVID-19 vaccines in patients with TETs. Our results indicate that most patients with TETs AEs such as local pain and swelling, fatigue, and headaches are self-limited and manageable. The use of immunosuppressive drugs to treat AD, or NSAIDs and acetaminophen to manage pain, could abrogate constitutional symptoms such as headaches, myalgia, and arthralgia. However, the use of these concomitant medications was comparable between TET patients who did and did not experience these AEs. Of note, patients with TETs were significantly less likely to experience myalgia following the second dose of both BNT162b2 and mRNA-1273 vaccines. This observation is of particular interest since patients with TETs, especially thymoma, are at increased risk of muscle inflammation when exposed to immune stimulation, such as with immune checkpoint inhibitors. 11, 12 Notwithstanding the decreased incidence of myalgia, it is advisable to initiate work-up for myositis if patients with TETs experience persistent and/or severe myalgia after receiving the BNT162b2 and mRNA-1273 vaccines. Despite underlying defects in immune tolerance and a predisposition to paraneoplastic autoimmunity, very few patients with TETs developed new AD after vaccination and the majority of those with pre-existing AD did not experience a disease flare, even though a large fraction of patients (61%) had WHO subtype B thymomas, the histological subtype most associated with paraneoplastic AD and immune-mediated toxicity upon immune stimulation. 4, 11, 12 The episodes that did occur were generally self-limited and did not require medical intervention. However, given the potential risk for AD flare or development, patient education and close monitoring is highly recommended following vaccination in this population. Limitations of this study include a small sample size due to the rarity of TETs, and selfreporting by participants, which can potentially add an element of subjectivity in assessment. Despite these limitations, we feel the results of this study are clinically meaningful and provide guidance to patients with TETs considering vaccination against COVID-19. Physician awareness of the tolerability of vaccination against COVID-19 among TET patients and the relatively low frequency of autoimmune flares, the majority of which are mild and selflimited, is key to promoting vaccination within this population. Two surveys conducted among individuals with AD regarding vaccination against COVID-19 found that the percentage of those willing to get vaccinated ranged from 54-61%. 13, 14 Key concerns among these patients regarding vaccination were the potential for inducing an autoimmune flare or experiencing other AEs. Notably, both surveys found that recommendations from their physicians regarding vaccination Thymic epithelial tumors: From biology to treatment Immune checkpoint inhibitors for treatment of thymic epithelial tumors: how to maximize benefit and optimize risk? Thymoma and paraneoplastic myasthenia gravis Paraneoplastic and therapy-related immune complications in thymic malignancies Paraneoplastic disorders in thymoma patients WT1 peptide-based immunotherapy for advanced thymic epithelial malignancies Immune checkpoints in thymic epithelial tumors: challenges and opportunities Emergency use authorization (EUA) for an unapproved product: Review memorandum. Pfizer-BioNTech. COVID-19 vaccine/ BNT162b2 FDA briefing document: Moderna COVID-19 vaccine Efficacy and tolerability of anti-programmed deathligand 1 (PD-L1) antibody (Avelumab) treatment in advanced thymoma Pembrolizumab for patients with refractory or relapsed thymic epithelial tumor: An open-label phase II trial Perspective of patients with autoimmune diseases on COVID-19 vaccination Vaccination against COVID-19: Expectations and concerns of patients with autoimmune and rheumatic diseases COVID-19 vaccines for moderately to severely immunocompromised people Mortality in hospitalized patients with cancer and coronavirus disease 2019: A systematic review and meta-analysis of cohort studies Evaluation of seropositivity following BNT162b2 messenger RNA vaccination for SARS-CoV-2 in patients undergoing treatment for cancer Three doses of an mRNA Covid-19 vaccine in solid-organ transplant recipients Randomized trial of a third dose of mRNA-1273 vaccine in transplant recipients